# A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

> **NCT05374226** · PHASE1 · UNKNOWN · sponsor: **Suzhou Kebo Ruijun Biotechnology Co., Ltd** · enrollment: 172 (estimated)

## Conditions studied

- Advanced Solid Tumors or Lymphomas

## Interventions

- **BIOLOGICAL:** JS019

## Key facts

- **NCT ID:** NCT05374226
- **Lead sponsor:** Suzhou Kebo Ruijun Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-31
- **Primary completion:** 2023-12-11
- **Final completion:** 2024-03-07
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05374226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05374226, "A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05374226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*